Skip to main
BNTX

BioNTech SE (BNTX) Stock Forecast & Price Target

BioNTech SE (BNTX) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 27%
Hold 27%
Sell 0%
Strong Sell 0%

Bulls say

BioNTech reported a robust financial position with approximately €16.7 billion in cash, cash equivalents, marketable securities, and trade receivables as of the end of Q3 2025, which supports its future growth and research initiatives. The company continues to make strides in its oncology pipeline, specifically with the ongoing evaluation of BNT323 in the Phase 3 DYNASTY-Breast02 trial, which is expected to contribute positively to its long-term performance. Additionally, BioNTech's development of an improved COVID-19 vaccine targeting multiple circulating sublineages demonstrates its commitment to innovation in infectious disease and strengthens its overall market position.

Bears say

The financial outlook for BioNTech is negatively impacted by several key risks, including the potential for negative clinical data from multiple drug candidates in its oncology pipeline and slower-than-anticipated market uptake for its products. Additionally, the company recorded a net loss per diluted share of €0.12 for the third quarter of 2025, with projections indicating a full-year net loss of €3.99, suggesting ongoing financial challenges. Furthermore, changing dynamics in the COVID-19 vaccine market, particularly due to a more restrictive regulatory environment in the U.S., may divert investor attention away from BioNTech's oncology initiatives.

BioNTech SE (BNTX) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 27% recommend Buy, 27% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BioNTech SE (BNTX) Forecast

Analysts have given BioNTech SE (BNTX) a Buy based on their latest research and market trends.

According to 11 analysts, BioNTech SE (BNTX) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $137.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $137.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BioNTech SE (BNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.